Vonova

Vonova operates at the intersection of neurovascular devices, brain-computer interfaces, neuromodulation, and minimally invasive neurosurgery. Its proposed differentiation is procedural rather than purely computational: the CerebroPlatform uses the venous system and image-guided catheter navigation to reach the brain without opening the skull. That approach targets a meaningful limitation of conventional cortical electrode procedures, where surgical access can carry infection, tissue-injury, recovery-time, and cost burdens. The company’s initial therapeutic emphasis on chronic pain gives the platform a defined clinical entry point, while its stated applicability to epilepsy, chronic subdural hematomas, diagnostics, and other neurological conditions creates a broader expansion thesis. The company is still at an early validation stage, supported by feasibility work, US patents, a 2024 MedTech Innovator cohort position, and pre-seed backing rather than commercial-scale financing. Relative to established open-brain neuromodulation approaches, Vonova’s central strategic bet is less invasive access through existing vascular anatomy.

Vonova’s trajectory reflects a transition from platform formation toward early clinical and commercial validation. Founded in 2021, the company was developing its catheter-based brain-access concept by 2023, when its cerebral catheter technology received external attention. In May 2024, it received non-equity assistance associated with MedTech Innovator, followed by a pre-seed round announced on August 20, 2024, led by SmartGateVC. Those milestones provided institutional support while the company advanced its CerebroPlatform and Cerebro Atlas System concepts. By June 2025, public attention had shifted toward the technology’s backing and minimally invasive route to the brain, suggesting progress in communicating the platform’s clinical and market rationale. With fewer than 10 employees and two visible executives, Vonova remains resource-constrained and technically focused. Its next inflection points are likely to be reproducible clinical evidence, a defined regulatory pathway, and financing sufficient to support device development and human studies.